Section of Gastroenterology - Dr. C. Bernstein

EDUCATION

UCLA Affiliated Training Program in Gastrointestinal Diseases, Los Angeles, CA 1989-1992

University of Manitoba,  Winnipeg, Manitoba
 Faculty of Medicine, 1981-1985
 Rotating Internship, 1985-1986
 Residency, Internal Medicine, 1986-1989

CERTIFICATION

-Internal Medicine-Royal College of Physicians and Surgeons of Canada
-American Board of Internal Medicine (1989)
-
Gastroenterology-Royal College of Physicians and Surgeons of Canada
-
American Board of Internal Medicine, Gastroenterology (1991)

LICENSURE

-The College of Physicians and Surgeons of Manitoba (1986-89, 1993- )
 -Licensure:  State of California (1989-1994)

APPOINTMENTS

-Bingham Chair in Gastroenterology Research 2009-present
-Canadian Academy of Health Sciences 2008-present
-Program Director, Gastroenterology Postgraduate Training Program, University of Manitoba, 2003-2008
-Head, Section of Gastroenterology, University of Manitoba, 2001-present
-Professor of Medicine, University of Manitoba, 2001-present
-Associate Professor of Medicine, University of Manitoba, 1997-2001
-Director, University of Manitoba Inflammatory Bowel Disease Clinical and Research Centre, 1994-present
-Assistant Professor of Medicine, University of Manitoba, 1993-1997
-Associate Investigator, CURE: UCLA/VA Gastroenteric Biology Center, 1993-1998
-Assistant Professor of Medicine, University of California, Los Angeles, 1992
-Associate Director, U.C.L.A. Inflammatory Bowel Disease Center, 1992
-Clinical Instructor of Medicine, University of California, Los Angeles, 1991
-Gastroenterology Coordinator- U.C.L.A. Small Bowel Transplantation Program, 1991
      

SELECTED AWARDS
-Canadian Association of Gastroenterology Young Clinicians Scholarship (1993)
-(elected) Fellow of American College of Gastroenterology (1999)
-Manitoba Medical Services Foundation Clinical Research Professorship (1999-2002)
-Nominated by Medicine II class for teacher of year (1998-1999)
-Rh Award for Outstanding Contributions to Scholarship and Research in the Health Sciences (2000)
-Crohn’s and Colitis Foundation of Canada Research Scientist Award (2001-2005)
-Nominated by Medicine II class for teacher of year (2000-2001)
-Voted by peers into Best Doctors Canada 2007-
-Crohn’s and Colitis Foundation of Canada Research Scientist Award (2006-2011)
-Canadian Academy of Health Sciences (elected as fellow) 2008-
-Bingham Chair in Gastroenterology Research 2009-

MAIN RESEARCH INTERESTS
-Epidemiology, etiology and outcomes in inflammatory bowel disease. -Screening and prevention in colorectal cancer
-Clinical trials in IBD, IBS and C difficile

Please see: http://www.ibdmanitoba.org/


CURRENT GRANTS
-Crohn’s and Colitis Foundation of Canada Research Scientist Award (2006-2011) “IBD: Defining the burden, finding the cause, and enhancing diagnosis and treatment.”  $375,000.
-Manitoba Medical Services Foundation (2007-2008). “Homocysteinemia and B vitamin status in inflammatory bowel disease: Is there an association to disease activity?” (Principle Investigator= K Vagianos, co-investigator= Charles Bernstein, Grant:  $40,000. 
-Crohn’s and Colitis Foundation of Canada Innovations in IBD competition (2007-2008). "Prevalence of the Uncultured Bacterial Candidate Phylum, TM7, in IBD Biopsy Tissue". (Co-principle investigator, Denis Krause): $49,000.
-Canadian Institutes of Health Research (2007-2010). “Comparing rheumatoid arthritis and inflammatory bowel disease by serology, gene studies, and ethnicity: Using commonalities and differences to develop etiologic hypotheses” (CIHR Team in Arthritis and Inflammatory Bowel Disease). (Co-investigators, Hani El-Gabalawy, Brenda Elias, Mark Silverberg, Xikui Wang). $975000.
-Crohn’s and Colitis Foundation of Canada (2007-2010). “Role of Bacteroides spp. and Escherichia coli in inflammatory bowel disease”. (Principle Investigator= Denis Krause, Co-investigator=Charles Bernstein): $439,934.
-Canadian Institute of Health Research-Manitoba Health Research Council Regional Partnership Program (2007-2009) “Understanding the biological, clinical, and psychosocial determinants of health outcomes in inflammatory bowel disease” (Co-investigators:  James F. Blanchard, M.D., Ph.D., Lesley Graff, Ph.D., John Walker, Ph.D., Lis Lix, PhD, William J Leslie, MD, Teresa Longobardi, PhD, Kathy Vagianos, MD)  $412,000
-Canadian Institute of Health Research-Manitoba Health Research Council Regional Partnership Program (2008-2013) “Understanding the biological, clinical, and psychosocial determinants of health outcomes in inflammatory bowel disease” (Co-investigators:  James F. Blanchard, M.D., Ph.D., Lesley Graff, Ph.D., John Walker, Ph.D., Lis Lix, PhD, William J Leslie, MD, Teresa Longobardi, PhD, Kathy Vagianos, MD)  $1,505,000
-The Celiac Association of Canada: JA Campbell Research Award (2009). “The prevalence of positive celiac serology in a large cohort of adult post menopausal women and its contribution to osteoporotic fractures and low bone density: A collaboration with the Study of Osteoporotic Fractures.” (Principle Investigator= Don Duerksen, Co-investigators= William Leslie, Charles Bernstein). $25000.


SELECTED PUBLICATIONS

Bernstein CN, Shanahan F, Weinstein WM.  Are we telling patients the truth about surveillance colonoscopy in ulcerative colitis?  Lancet 1994: 343; 71-74.

Bernstein CN, Boult IF, Greenberg HM, van der Putten W, Duffy G, Grahame GR.  A prospective randomized comparison between small bowel enteroclysis and small  bowel follow-through in Crohn's disease.  Gastroenterology 1997; 113: 390-398.

Bernstein CN, Blanchard JF, Rawsthorne P, Wajda A.  The epidemiology of Crohn's disease and ulcerative colitis in a central Canadian province: A population-based study.  American Journal of Epidemiology 1999; 149: 916-924.

Bernstein CN, Blanchard JF, Leslie WD, Wajda A, Yu N.  The incidence of fractures among patients with IBD: A population-based study.  Annals of Internal Medicine 2000; 133: 795-799.

Bernstein CN, Sargent M, Rector E.  Alteration in expression of beta-2 integrins on lamina propria lymphocytes in ulcerative colitis and Crohn’s disease. Clinical Immunology 2002; 104: 67-72. 

Bernstein CN, Leslie WD, Leboff M. AGA Technical Review: Osteoporosis in
gastrointestinal diseases.  Gastroenterology 2003; 124: 795-841.

Bernstein CN, Nayar G, Hamel A, Blanchard JF. A pursuit of animal borne infections in the mucosa of subjects with inflammatory bowel disease and population-based controls.  Journal of Clinical Microbiology 2003; 41:4986-90.

Bernstein CN, Metge C, Blanchard JF, Yogendran M.  Does the use of 5-aminosalicylates in inflammatory bowel disease prevent the development of colorectal cancer? American Journal of Gastroenterology 2003; 98: 2784-2788.

Bernstein CN, Blanchard JF, Rawsthorne P, Collins MT. A population-based case control study of seroprevalence of Mycobacterium paratuberculosis in patients with Crohn's disease and ulcerative colitis. Journal of Clinical Microbiology 2004; 42:1129-1135.

Pitz M, Cheang M, Bernstein CN. Defining the predictors of the placebo response in irritable bowel syndrome. Clinical Gastroenterology and Hepatology 2005; 3: 237-47.

Eckburg P, Bik EM, Bernstein CN, Purdom E, Dethlefsen L, Sargent M, Gill SR, Nelson K, Relman DA.  Diversity of the human intestinal microbial flora. Science; 2005; 308:
1635 -1638.

Bernstein CN, Wajda A, Blanchard JF. The clustering of other chronic inflammatory diseases in IBD: A population-based study.  Gastroenterology 2005; 129:827-36.

Bernstein CN, Rawsthorne, P, Cheang M, Blanchard JF. A population-based case control study of potential risk factors for IBD. American Journal of Gastroenterology 2006; 101(5):993-1002.

Bernstein CN, Wajda  A, Svenson LW, MacKenzie A, Koehoorn M, Jackson M, Fedorak R, Israel D, Blanchard JF.  The epidemiology of inflammatory bowel disease in Canada: A population-based study: A population-based study. American Journal of Gastroenterology 2006; 101:1559-68.

Bernstein CN. The placebo effect for gastroenterology: Tool or torment. Clinical Gastroenterology and Hepatology 2006; 4:1302-8.

Kotlowski R, Bernstein CN, Sepehri S, Krause DO. High prevalence of Escherichia coli belonging to the B2+D phylogenetic group in inflammatory bowel disease.  Gut 2007; 56: 669-75.

Bernstein CN, Blanchard JF, Wajda A. The incidence of arterial thromboembolic diseases in inflammatory bowel disease: A population-based study. Clinical Gastroenterology and Hepatology 2008; 6: 41-5.

Walker JR, Ediger JP, Graff LA, Greenfeld JM, Clara I, Lix L, Rawsthorne P, Miller N, Rogala L, McPhail C, Bernstein CN. The Manitoba IBD Cohort Study: A population-based study of the prevalence of lifetime and twelve-month anxiety and mood disorders. American Journal of Gastroenterology 2008; 103:1989-97.

Bernstein CN, Shanahan F. Disorders of a modern lifestyle– reconciling the epidemiology of inflammatory bowel diseases. Gut 2008; 57:1185-91.

Clara I, Lix LM, Walker JR, Graff LA, Miller N, Rogala L, Rawsthorne P, Bernstein CN. The Manitoba IBD Index: Evidence for a New and Simple Indicator of  IBD Activity. American Journal of Gastroenterology 2009; (in press).


MISCELLANEOUS
-Editor of annual Yearbook in IBD, Remedica Publishers, 6th volume in press 2009

-Scientific Director of annual University of Manitoba GI symposium, 14th year, 2009